Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 2:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Inflammatory Disorder Clear all
Withdrawn Phase 4 Interventional

Manuka Eye Droops for Treatment of Allergy

NCT03862053
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Manuka honey
Drug
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Germantown, Tennessee • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Sep 14, 2026, 2:56 AM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients

NCT01284062
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Anrukinzumab, placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2014 · Synced Sep 14, 2026, 2:56 AM EDT
Completed Phase 3 Interventional Results available

Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age

NCT05856227
View directory record Official record
Conditions
Neonatal Sepsis
Interventions
Ceftobiprole medocaril
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
3 Days to 3 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Evanston, Illinois • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Sep 14, 2026, 2:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacokinetics (Movement of Drugs Within the Body), Safety and Tolerability of Brazikumab in Healthy Chinese and White Participants

NCT05033431
View directory record Official record
Conditions
Healthy Participants
Interventions
Brazikumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Sep 14, 2026, 2:56 AM EDT
Recruiting Phase 2 Interventional

A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.

NCT07215702
View directory record Official record
Conditions
Sepsis, Acute Kidney Injury
Interventions
AZD4144, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
16
States / cities
Phoenix, Arizona • Newport Beach, California • Kansas City, Kansas + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 14, 2026, 2:56 AM EDT
Completed Phase 4 Interventional Results available

Dose Escalation and Remission (DEAR)

NCT00652145
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
mesalamine
Drug
Lead sponsor
James Lewis
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
8
States / cities
Naples, Florida • Winter Park, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Sep 14, 2026, 2:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Dose Ethnobridging PK Study in Healthy Subjects

NCT03750565
View directory record Official record
Conditions
Inflammatory Bowel Diseases, IBD
Interventions
TD-1473 - Dose A, TD-1473 - Dose B, TD-1473 - Dose C, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Sep 14, 2026, 2:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Vitamin D-Enriched Mushrooms on Vitamin D Status and Immune Function and Inflammatory Status in Adults

NCT05559112
View directory record Official record
Conditions
Vitamin D Deficiency
Interventions
Vitamin D-enriched mushrooms, Study Powder
Other
Lead sponsor
Purdue University
Other
Eligibility
30 Years to 69 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Sep 14, 2026, 2:56 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease

NCT00072839
View directory record Official record
Conditions
Crohn's Disease
Interventions
ALX-0600, placebo, teduglutide 0.05, teduglutide 0.2 mg, Teduglutide 0.05 dose, teduglutide 0.1 mg dose
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
21
States / cities
Tucson, Arizona • Lakewood, Colorado • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Sep 14, 2026, 2:56 AM EDT
Suspended Not applicable Interventional

Adjunctive Treatment With Vitamin D3 in Patients With Active IBD

NCT04225819
View directory record Official record
Conditions
IBD, Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Vitamin D3 Deficiency
Interventions
Vitamin D3, Placebo
Dietary Supplement · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 14, 2026, 2:56 AM EDT
Completed No phase listed Observational

Immune Responses to Antigens in Non-infectious Eye Inflammatory Diseases

NCT00357071
View directory record Official record
Conditions
Eye Diseases
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
6 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 14, 2026, 2:56 AM EDT
Completed No phase listed Observational

Screening for NEI Clinical Studies

NCT00001734
View directory record Official record
Conditions
Conjunctivitis, Iritis, Keratitis, Retinitis, Uveitis
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
2 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 14, 2026, 2:56 AM EDT
Completed Phase 2 Interventional

Remotely Administered Diet Intervention to Impact Symptom Burden in Myeloproliferative Neoplasm

NCT04744974
View directory record Official record
Conditions
Myeloproliferative Neoplasm
Interventions
Diet intervention
Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Sep 14, 2026, 2:56 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Genetic Variation and Immune Responses After Injury

NCT00294697
View directory record Official record
Conditions
Sepsis, Pneumonia, Trauma, Burn, Injury
Interventions
Not listed
Lead sponsor
National Institute of General Medical Sciences (NIGMS)
NIH
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2010 · Synced Sep 14, 2026, 2:56 AM EDT
Recruiting Phase 1 Interventional

Mitigating the Pro-inflammatory Phenotype of Obesity

NCT04934228
View directory record Official record
Conditions
Blood Pressure, Diabetes, Obesity, Insulin Resistance, Diuretics Drug Reactions, Sympathetic Nerve Activity
Interventions
Hydrochlorothiazide 12.5Mg Tab, Clonidine Pill, Placebo
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 79 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 14, 2026, 2:56 AM EDT
Completed No phase listed Observational

Impact of Aminoglycosides in Hypotensive Septic Oncology Patients

NCT05045963
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Septicemia
Interventions
Electronic Health Record Review
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 14, 2026, 2:56 AM EDT
Completed Phase 2 Interventional

Examination of Pirfenidone (Esbriet®) Therapy in Coal Workers' Pneumoconiosis With Pulmonary Fibrosis

NCT04461587
View directory record Official record
Conditions
Coal Workers' Pneumoconiosis (Complicated)
Interventions
Pirfenidone
Drug
Lead sponsor
Pulmonary Research of Abingdon, LLC
Other
Eligibility
40 Years to 79 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Abingdon, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Sep 14, 2026, 2:56 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Sep 14, 2026, 2:56 AM EDT
Recruiting No phase listed Observational

Evaluation of Pro-Inflammatory Leukocyte Activity in Patients Undergoing Cardiac Surgery

NCT04299828
View directory record Official record
Conditions
Congenital Heart Disease, Coagulation
Interventions
Discarded blood samples
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 14, 2026, 2:56 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

NCT03105128
View directory record Official record
Conditions
Crohn's Disease
Interventions
placebo for risankizumab, risankizumab IV, risankizumab SC
Drug
Lead sponsor
AbbVie
Industry
Eligibility
16 Years to 80 Years
Enrollment
931 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
117
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 94 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Sep 14, 2026, 2:56 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Anti-inflammatory Effects of Simvastatin

NCT04638400
View directory record Official record
Conditions
Inflammation, Atherosclerosis, Hypercholesterolemia
Interventions
Simvastatin 40mg, Ezetimibe 10mg
Drug
Lead sponsor
paresh Dandona
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Sep 14, 2026, 2:56 AM EDT
Terminated Phase 2 Interventional Results available

A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)

NCT04814368
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
canakinumab, LNA043, Placebo to canakinumab
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
La Mesa, California • Clearwater, Florida • Sunrise, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 14, 2026, 2:56 AM EDT
Recruiting No phase listed Observational

High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy

NCT04331639
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn Disease, Ulcerative Colitis, Vitamin D Deficiency
Interventions
vitamin D3
Dietary Supplement
Lead sponsor
Boston Children's Hospital
Other
Eligibility
5 Years to 25 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Sep 14, 2026, 2:56 AM EDT
Completed Not applicable Interventional

SMART-IBD App Trial

NCT06023667
View directory record Official record
Conditions
Inflammatory Bowel Diseases, IBD, Crohn Disease, Ulcerative Colitis
Interventions
SMART-IBD
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
13 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Sep 14, 2026, 2:56 AM EDT